The Australian Lung Cancer Conference (ALCC) 2025 was held in Adelaide, Australia, from February 19-21, 2025, with the theme “Evolution and Revolution in Lung Cancer.” With the upcoming implementation of Australia's National Lung Cancer Screening Program (NLCSP) in July 2025, the conference provided an important opportunity for experts to discuss the program's effective operation, anticipated challenges, and healthcare innovations using AI technology.
In Australia, lung cancer is the fifth most common cancer and the leading cause of cancer deaths. According to the Australian Institute of Health and Welfare (AIHW), by 2024, there will be an estimated 15,100 new cases of lung cancer and nearly 9,000 deaths.
As a result, the Australian government has been discussing the introduction of a national lung cancer screening program since 2019, with an official announcement in 2023 and a budget of A$260 million, with full implementation set to begin in July 2025. The program will provide early screening using low-dose chest CT (LDCT) for high-risk individuals, with pilot projects already underway in select hospitals and research institutions.
Currently, the Australian government is providing preliminary education through the NLCSP website and encouraging more patients to participate in regular screening. At ALCC 2025, there was a lively discussion on how AI-based solutions can improve the lung cancer screening process amidst these changes.
ALCC 2025 highlighted the importance of AI-powered image analytics in the early detection of diseases such as lung cancer. In particular, it is becoming an important trend in the lung cancer screening process to comprehensively assess the patient's lung health and perform more precise quantitative analysis using AI technology.
At the conference, CorelineSoft introduced AVIEW LCS Plus, an AI-based lung cancer screening solution, and actively promoted how AI can contribute to early diagnosis and quantitative analysis of lung cancer to medical professionals and policy makers.
At ALCC 2025, CorelineSoft also co-exhibited with ParagonCare, our Australian medical distribution partner, to further solidify our collaboration. ParagonCare is a large medical distributor that operates medical devices and solutions throughout Australia, with a strong distribution network, especially in hospitals and radiology.
Through this conference, CorelineSoft confirmed that most of the key requirements for AI solution providers at the NLCSP can be met by AVIEW LCS Plus, which is important for further strengthening Coreline's position in the Australian lung cancer screening market in the future.
The conference also featured key opinion leaders (KOLs), policy makers, and partners who play a key role in the NLCSP, and CorelineSoft was successful in networking with them. One of the highlights was the in-depth discussion on how AI technology can be used in lung cancer screening programs.
ALCC 2025 was more than just an opportunity for Coreline Soft to showcase its technology, it was an important opportunity to strengthen partnerships and set strategic direction in the Australian lung cancer screening market. The key insights gained from the conference will help further clarify CorelineSoft's direction for successful participation in the NLCSP.
Contact us
General inquiries
Business Department
Overseas Business Department
Customer Service Team
IR-related inquiries
List